We are a biopharmaceutical company focused on the acquisition, development and
commercialization of novel targeted therapies covering a spectrum of
blood-related cancers that offer a unique benefit to patients and healthcare
providers. Our goal is to build a profitable company by generating income from
products we develop and commercialize, either alone or with partners. We are
currently concentrating our efforts on treatments that target blood-related
cancers where there is an unmet medical need. In particular, we are primarily
focused on evaluating pacritinib for the treatment of adult patients with
myelofibrosis and the further development of PIXUVRI worldwide, for which our
partner, Les Laboratoires Servier and Institut de Recherches Internationales
Servier, or collectively Servier, has commercialization rights outside the
United States, or the U.S.
PIXUVRI
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical
properties.